ETF Managers Group, LLC Paratek Pharmaceuticals, Inc. Transaction History

ETF Managers Group, LLC

$2.78 Billion
Q1 2023

A detailed history of ETF Managers Group, LLC transactions in Paratek Pharmaceuticals, Inc. stock. As of the latest transaction made, ETF Managers Group, LLC holds 18,339 shares of PRTK stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,339

Previous 13,849 32.42%

Holding current value

Previous $25,000 84.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$1.37 - $2.54 $6,151 - $11,404	4,490 Added 32.42%	18,339 $46,000
Q4 2022 Mar 23, 2023	SELL	$1.67 - $2.51 $3,909 - $5,875	-2,341 Reduced 14.46%	13,849 $25,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $2.93 $2,003 - $2,994	-1,022 Reduced 5.94%	16,190 $42,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $3.09 $3,439 - $6,142	1,988 Added 13.06%	17,212 $35,000
Q1 2022 May 13, 2022	BUY	$2.94 - $4.77 $149 - $243	51 Added 0.34%	15,224 $45,000
Q4 2021 Feb 14, 2022	SELL	$4.07 - $5.3 $8,140 - $10,600	-2,000 Reduced 11.65%	15,173 $68,000
Q3 2021 Nov 15, 2021	BUY	$4.7 - $7.24 $15,646 - $24,101	3,329 Added 24.05%	17,173 $85,000
Q2 2021 Aug 16, 2021	SELL	$6.81 - $10.93 $932 - $1,497	-137 Reduced 0.98%	13,844 $94,000
Q1 2021 May 17, 2021	SELL	$6.14 - $8.31 $50,458 - $68,291	-8,218 Reduced 37.02%	13,981 $96,000
Q4 2020 Feb 16, 2021	SELL	$4.58 - $7.14 $14,816 - $23,097	-3,235 Reduced 12.72%	22,199 $138,000
Q3 2020 Nov 16, 2020	BUY	$4.19 - $6.69 $53,900 - $86,060	12,864 Added 102.34%	25,434 $140,000
Q2 2020 Aug 14, 2020	BUY	$2.97 - $5.22 $37,332 - $65,615	12,570 New	12,570 $64,000

Others Institutions Holding PRTK

# of Institutions

Shares Held

1.54M

Call Options Held

Put Options Held

View Full List

About Paratek Pharmaceuticals, Inc.

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

More about PRTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.

Account

ETF Managers Group, LLC Paratek Pharmaceuticals, Inc. Transaction History